Tempus ECG-AF vs Impala
AI Verdict
Choose Tempus ECG-AF if…
Choose Tempus ECG-AF if your primary objective is to proactively identify patients aged 65 or older at an increased risk of developing new-onset atrial fibrillation within the next 12 months. This AI-based software solution is ideal for integrating into existing healthcare facility systems to enhance screening protocols and guide earlier follow-up for AF risk management.
View Tempus ECG-AF →Choose Impala if…
Choose AliveCor's Impala if you are a healthcare professional requiring a portable, AI-powered 12-Lead ECG device for rapid, on-demand cardiac assessment in various clinical or emergency settings. This tool is best suited for quickly acquiring diagnostic-quality ECG data and leveraging AI to detect life-threatening cardiac conditions, including heart attacks, where mobility and immediate results are crucial.
View Impala →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Tempus ECG-AF | Impala |
|---|---|---|
| Pricing | Contact vendor | Contact for pricing |
| Deployment | Software solution, integrated into healthcare facility systems with advanced cardiology algorithms. | Portable device, integrated with mobile applications/platforms. |
| BAA Available | Yes AI-estimated | Yes AI-estimated |
| FDA Status | Yes AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
ImpalaTool B (Impala) emphasizes portability and ease of use with its reduced leadset for 12-lead ECG acquisition and integration with mobile applications, making it highly adaptable for rapid assessments. While Tool A integrates into existing facility systems, Tool B's design directly addresses user interaction and setup simplicity for a broader range of clinical settings.
Clinical Value
ImpalaBoth tools offer significant clinical value, but Tool B (Impala) provides immediate, critical diagnostic information by acquiring a full 12-lead ECG and detecting 'life-threatening cardiac conditions, including heart attacks.' Tool A's predictive risk assessment for AF is valuable for long-term management but addresses a less acute need than real-time heart attack detection.
Pricing & Value
Tempus ECG-AFTool A (Tempus ECG-AF) offers clear financial transparency by providing specific CMS reimbursement codes (CPT 0764T and CPT 0765T) and a Medicare rate, which significantly aids healthcare providers in assessing its economic value. Tool B (Impala) only states 'contact for pricing' with no further details, making its financial implications less clear.
Enterprise Readiness
TieBoth tools are FDA-cleared, HIPAA compliant, and have BAAs, demonstrating foundational enterprise readiness. Tool A is designed for integration into 'healthcare facility systems,' while Tool B, despite being a portable device, also offers an 'enterprise platform' for managing patient data and integrating into existing workflows, suggesting comparable capabilities for different deployment models.
Innovation
ImpalaBoth tools are innovative, but Tool B (Impala) stands out with its combined hardware and software innovation, enabling a full diagnostic 12-lead ECG from a reduced leadset on a portable device. This significantly enhances practical ECG acquisition and immediate diagnostic utility in various settings. Tool A's predictive AI for AF risk from standard ECGs is also novel but less impactful in terms of device and acquisition methodology.
Support & Docs
ImpalaAliveCor (Tool B) provides more extensive and specific support resources, including readily available user manuals for its related products, a dedicated physician portal (KardiaPro) for data management, and mentions of 24/7 monitoring services. Tempus (Tool A) offers general company support channels but less specific documentation for its ECG-AF product in the search results.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Tempus ECG-AF | Impala |
|---|---|---|
| Name | Tempus ECG-AF | Impala |
| Company | Tempus AI, Inc. | AliveCor |
| Primary Purpose | Identifies patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months. | Portable, AI-powered 12-Lead ECG device for healthcare professionals to acquire ECGs and detect life-threatening cardiac conditions. |
| Key Technology | AI-based algorithm for 12-lead ECG analysis, trained on over 1.5 million ECGs. | AI technology (KAIu2122 12L) for cardiac determinations, uses a reduced leadset (single cable with 5 electrodes). |
| Target Patient Population/Conditions | Patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery, to detect new onset Atrial Fibrillation (AF) within 12 months. | Healthcare professionals for rapid cardiac assessment, detects life-threatening cardiac conditions, including heart attacks. |
| ECG Lead Acquisition/Analysis | Analyzes 12-lead ECG recordings (compatible with FDA authorized resting 12-lead ECGs from GE Medical Systems and Philips Medical Systems). | Acquires 4 standard diagnostic-bandwidth leads, derives 4 standard diagnostic-bandwidth leads, and software generates remaining leads for a 12-Lead recording. |
Videos
Demos, reviews, and walkthroughs featuring Tempus ECG-AF and Impala.
Frequently Asked Questions
More Comparisons
More matchups featuring Tempus ECG-AF or Impala
Backers
Who funded each tool's parent company.